Last reviewed 2026-04-20 · How we verify

Droxar (DROXICAM)

Phase 2 active Small molecule Quality 24/100

Droxar (generic name: DROXICAM) is a droxicam drug. It is currently in Phase 2 development.

Droxar works by blocking enzymes that produce prostaglandins, which are hormone-like substances that cause pain and inflammation.

Droxar (DROXICAM) is a small molecule drug in the droxicam class, but specific details about its development, approval status, and commercial status are not available. As a droxicam, it is likely a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes. However, without further information, it is unclear what specific indications Droxar is approved for or its pharmacokinetic properties. Further research is needed to determine its commercial status and key safety considerations. As a result, Droxar's clinical use and potential risks are currently unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DROXICAM
Drug class	droxicam
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. By blocking these messengers, Droxar helps to reduce pain and inflammation. This can be especially helpful for people with conditions like arthritis or other inflammatory diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Droxar CI brief — competitive landscape report
Droxar updates RSS · CI watch RSS

Frequently asked questions about Droxar

What is Droxar?

Droxar (DROXICAM) is a droxicam drug.

How does Droxar work?

Droxar works by blocking enzymes that produce prostaglandins, which are hormone-like substances that cause pain and inflammation.

What is the generic name of Droxar?

DROXICAM is the generic (nonproprietary) name of Droxar.

What drug class is Droxar in?

Droxar belongs to the droxicam class. See all droxicam drugs at /class/droxicam.

What development phase is Droxar in?

Droxar is in Phase 2.

Drug class: All droxicam drugs
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing